Up-front temozolomide in elderly patients with glioblastoma

By Laigle-Donadey Florence   Figarella-Branger Dominique   Chinot Olivier   Taillandier Luc   Cartalat-Carel Stéphanie   Honnorat Jérôme   Kaloshi Gentian   Delattre Jean-Yves   Sanson Marc  

Journal of Neuro-Oncology, Vol. 99, Iss. 1, 2010-08 ,pp. : 89-94

Springer Publishing Company

Access to resources Recommend Favorite

Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade

By Buckner Jan   O’Fallon Judith   Dinapoli Robert   Schomberg Paula   Farr Gist   Schaefer Paul   Giannini Caterina   Scheithauer Bernd   Ballman Karla  

Journal of Neuro-Oncology, Vol. 84, Iss. 3, 2007-09 ,pp. : 279-286

Springer Publishing Company

Access to resources Recommend Favorite

Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors

By Habets Esther   Taphoorn Martin   Nederend Sylvie   Klein Martin   Delgadillo Daniel   Hoang-Xuan Khê   Bottomley Andrew   Allgeier Anouk   Seute Tatjana   Gijtenbeek Anja   Gans Jan   Enting Roelien   Tijssen Cees   den Bent Martin   Reijneveld Jaap  

Journal of Neuro-Oncology, Vol. 116, Iss. 1, 2014-01 ,pp. : 161-168

Springer Publishing Company

Access to resources Recommend Favorite

Higher dosing of temozolomide? Regression of an anaplastic oligoastrocytoma over more than three years

By Koch Dorothee   Wick Wolfgang  

Journal of Neuro-Oncology, Vol. 77, Iss. 2, 2006-04 ,pp. : 219-220

Springer Publishing Company

Access to resources Recommend Favorite

A Multicenter Cohort Study of Dose-Dense Temozolomide (21 of 28 Days) for the Treatment of Recurrent Anaplastic Astrocytoma or Oligoastrocytoma

By Neyns Bart   Chaskis Cristo   Joosens Eric   Menten Johan   D'Hondt Lionel   Branle Fabrice   Sadones Jan   Michotte Alex  

Cancer Investigation, Vol. 26, Iss. 3, 2008-03 ,pp. : 269-277

Informa Healthcare

Access to resources Recommend Favorite